Amir Navaei

Amir Navaei

Auto-generated profile, based on publicly available information

Amir Navaei

Department of Pathology & Immunology Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in ASAIO Journal
Verified
Journal Article
Closed access
LSLynne Singleton
Lynne Singleton
CKCurtis Kennedy
Curtis Kennedy
BPBlessy Philip
Blessy Philip
ANAmir Navaei
Amir Navaei
SBSaleh Bhar
Saleh Bhar
AOAndrea Ontaneda
Andrea Ontaneda
Bleeding is a common complication of extracorporeal membrane oxygenation (ECMO), is multifactorial, and results in significant morbidity and mortality. Pulmonary hemorrhage represents a serious adverse event in pediatric patients on ECMO and remains a challenging complication to manage. Its occurrence highlights the importance of identifying treatments that address bleeding complications in this population. This retrospective cohort study, from January 2018 to August 2022, explores the use of inhaled tranexamic acid (TXA), a clot-stabilizing agent, in 53 pediatric ECMO patients with new pulmonary hemorrhage. Primary diagnoses included respiratory failure (34%) and structural abnormalities (34%), such as congenital heart defects, congenital diaphragmatic hernia, and tracheal stenosis, with viral pneumonia being the leading cause of respiratory failure (47%). Results indicated that 48 of 53 (91%) patients showed cessation of pulmonary hemorrhage within 48 hours of inhaled TXA administration as measured by a decrease in our institution-specific bleeding scale from moderate to minor or no bleeding. In ECMO-managed pediatric patients with pulmonary hemorrhage, treatment with inhaled TXA demonstrated safety, with no observed adverse effects, and showed promising signs of contributing to the cessation of bleeding.

16 August 2026 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
VKVadim Kostousov
Vadim Kostousov
KBKaren Bruzdoski
Karen Bruzdoski
ANAmir Navaei
Amir Navaei
JTJun Teruya
Jun Teruya
Introduction: Bivalirudin is an alternative anticoagulant to heparin and is widely used in pediatric extracorporeal life support (ECLS). Its activity is monitored using activated partial thromboplastin time (aPTT) and/or more specific tests such as plasma‐diluted thrombin time (dTT). A new automated thrombin generation assay (TGA) has also shown promise in evaluating the hemostatic response in anticoagulated patients; however, its utility for monitoring bivalirudin or other anticoagulants in pediatrics remains unknown. We aimed to evaluate TGA in pediatric patients treated with bivalirudin and to compare it with that observed in patients receiving other commonly used anticoagulants. Methods: TGA, aPTT, aPTT with hepzyme, dTT, INR were measured in 30 specimens from 12 pediatric ECLS patients anticoagulated with bivalirudin. In addition, TGA, anti‐Xa assay, and INR were measured in samples from children receiving enoxaparin ( n = 22, 10 patients), heparin ( n = 16, 8 patients), and warfarin ( n = 19, 6 patients). Results: TGA lag ratio showed a strong correlation with bivalirudin concentration as measured by dTT and ROC analysis demonstrated that a Lag ratio > 2.0 predicted specimens within the therapeutic range for bivalirudin (sensitivity 0.88, specificity 0.67, accuracy 0.79). Interestingly, samples containing endogenous heparin‐like substances exhibited paradoxically enhanced thrombin generation, despite having the highest aPTT values. Enoxaparin effect was associated with a reduction in thrombin peak and endogenous thrombin potential (ETP) suppression, while both heparin and warfarin led to a prolonged lag time, along with decreased peak and greater ETP suppression. Conclusion: TGA shows promise in evaluating bivalirudin anticoagulation and is capable of detecting anticoagulant activity across both subtherapeutic and therapeutic levels of other agents commonly used in pediatric patients.